Background Major depressive disorder is one of the most common, burdensome, and costly
psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological …

Background The question of which antipsychotic drug should be preferred for the treatment
of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a …

Background Conventional meta-analyses have shown inconsistent results for efficacy of
second-generation antidepressants. We therefore did a multiple-treatments meta-analysis, …

Background Adverse mental health consequences of COVID-19, including anxiety and
depression, have been widely predicted but not yet accurately measured. There are a range of …

Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …

Background Long-COVID refers to a variety of symptoms affecting different organs reported
by people following Coronavirus Disease 2019 (COVID-19) infection. To date, there have …

Background Neurological and psychiatric sequelae of COVID-19 have been reported, but
more data are needed to adequately assess the effects of COVID-19 on brain health. We …

Background Although expert opinion has asserted that there is an increased risk of violence
in individuals with schizophrenia and other psychoses, there is substantial heterogeneity …

In the European Union, more than 400 000 individuals are homeless on any one night and
more than 600 000 are homeless in the USA. The causes of homelessness are an interaction …

Background Antidepressant drugs can promote remission from acute depressive episodes.
Our aim was to establish how long such treatments should be continued to prevent relapse. …